4-(TRIFLUOROMETHYLTHIO)BENZALDEHYDE

We are 4-(TRIFLUOROMETHYLTHIO)BENZALDEHYDE CAS:4021-50-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-(TRIFLUOROMETHYLTHIO)BENZALDEHYDE
CAS.NO:4021-50-5
Synonyms:4-(trifluoromethylsulfanyl)benzaldehyde;
Molecular Formula:C8H5F3OS
Molecular Weight:206.18500
 
Physical and Chemical Properties:
Density:1.31;
Melting point:29-31oC;
Boiling point:219oC;
Flash point:212oF;
Index of Refraction:1.511;
 
Specification:
Appearance:White to yellow low melting solid
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

4-(TRIFLUOROMETHYLTHIO)BENZALDEHYDE


Related News: The company’s short-term plan is to move from a purely chemical intermediate manufacturer to a formula active material supplier, and its long-term goal is to become a solution provider in the selected segment. In the future, this business is expected to become a new growth point for the company’s profit.Ácido (Z) -2- (2-aminotiazol-4-il) -2- (hidroxiimino) acético CAS:66338-96-3 The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.4-Hydroxy-3-methoxybenzylamine hydrochloride Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.2-methoxy-3-nitropyridine CAS:20265-35-4 Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
Bivalirudin View Details
2-(2-chloroethoxy)-N-(oxomethylidene)benzenesulfonamide View Details
N-[3-(methylamino)propyl]oxolane-2-carboxamide View Details
1-Chloro-5-iodopentane manufacturer 2-Methylphenyl isothiocyanate manufacturer cytosine manufacturer 2-[1-(Mercaptomethyl)Cyclopropyl]Acetic Acid manufacturer 1-BroMo-N-phenylcarbazole manufacturer